TickerTalks
Browse all tickers →
TickerTalks›$XGN
XGXGN

Exagen Inc.

Hot onWhy it's trendingX mentions rising faster than the marketBullish-leaning chatter
$XGN·$211M·Medical - Diagnostics & Research·Healthcare
$8.42-0.7%YTD+39.7%1Y-21.3%
Price updated 10m ago·X counts updated 2d ago
XGXGN
$XGNExagen Inc.
$8.42-0.70%6 posts
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $XGN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

6X posts · last 7 days
Sep 11Sep 27
Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-28

Exagen posts are bullish following the diagnostics sector rotation and the rheumatologist expert-transcript confirmation of the AVISE bull thesis. Bulls cite XGN at sub-2.5x revs vs sector 9-10x and $8 double for common holders on the Jasper Ridley collaboration. Skeptics essentially absent.

Read what X is saying about $XGN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $XGN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Exagen is a $211M autoimmune-diagnostics microcap at 2.5x revs with real growth — the -21% t12m tape is the pre-inflection setup.

Exagen is a $211M autoimmune-diagnostics company (AVISE lupus/APS/RA panels) delivering real growth at a discounted multiple — the setup is a possible diagnostics rerating.

The picture:

  • Revenue is growing consistently: last four quarters +14% to +38% YoY, Q1 revenue $17.3M with 59% gross margin. Latest EPS beats: +32%, +29% — the direction is right even at negative absolute numbers. Analyst 2026 consensus $73.9M revenue, EPS narrowing toward zero.
  • The multiple is compressed: PS 1.5x on a diagnostics name with 60% gross margins is unusual — comparable diagnostics run 5-10x. TTM PE -5, op margin -21%, ROIC -33%. Cash burn is real (FCF yield -14%).
  • Insider tape is neutral: Sept 1 Jeffrey Black received 1,571 award shares at $3.02 and sold 20,614 at $7.22 — the S-Sale value ($149k) is significant for a microcap officer. Sept 21 'Moderate Buy' consensus from analysts is the sell-side stamp.

The bull path is Nov 3 Q3 continuing the +30% EPS surprise cadence plus Jasper Ridley collaboration progress. The bear path is a capital raise at this price given the -14% FCF yield, or reimbursement-rate pressure on AVISE CTD.

Agrees with X sentimentThe X thesis (XGN at sub-2.5x revs vs sector 9-10x, Jasper Ridley collaboration, expert-transcript AVISE confirmation) matches what the fundamentals show — the multiple is meaningfully discounted for a real diagnostics grower. The one thing X skips is the -14% FCF yield / cash-burn duration; sizing accordingly is prudent even if the direction is right.

What to watch: Nov 3 Q3 earnings (consensus -$0.19 EPS). Also any 8-K on capital raise / dilution or reimbursement contract with a major payer for the AVISE CTD panel.

On the calendar: 2026-11-03 — Q3 earnings

cash burn

Read the AI verdict on $XGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops and sells AVISE diagnostic tests used by rheumatologists to diagnose and monitor lupus and related autoimmune diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $XGN.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $XGN

Partial — Develops and sells AVISE diagnostic tests used by rheumatologists to diagnose and monitor lupus and related autoimmune diseases.

Industry benchmark

18-name peer basket
+46.1%YTD
+85.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-33.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-20.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-114%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
58.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.13$-0.19+32.1%
Q1 2026May 11, 2026$-0.17$-0.24+29.2%
Q4 2025Mar 10, 2026$-0.20$-0.200.0%
Q3 2025Nov 4, 2025$-0.31$-0.16-97.6%
Next earningsTue, Nov 3·consensus EPS $-0.19

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$17.3M+11.7%59.0%-19.7%$-0.17$-10.6M
Q4 FY25$16.6M+21.8%55.4%-29.9%$-0.21$-3.1M
Q3 FY25$17.2M+37.9%58.4%-18.0%$-0.31$2.7M
Q2 FY25$17.2M+14.2%60.4%-15.3%$-0.21$-3.1M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$73.9M$73.7M – $74.1M-$0.65-$0.66 – -$0.645
FY27$81.3M$81.2M – $81.3M-$0.49-$0.50 – -$0.495
FY28$92.0M$90.5M – $93.2M-$0.33-$0.37 – -$0.293
FY29$105.0M$103.9M – $105.9M-$0.09-$0.09 – -$0.081
FY30$114.7M$113.6M – $115.8M-$0.05-$0.05 – -$0.052

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.61%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+24.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+76.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β2.105-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 1Jeffrey G. BlackCFO20.6K sh$149K
+ 7 other (7 awards) in window

See when $XGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 98-K — Item 5.07: Shareholder vote
AI summary

Exagen Inc. held its 2026 Annual Meeting on June 9, 2026. Stockholders elected two Class I directors — Tina S. Nova, Ph.D. (8.09M votes for) and Scott Kahn, Ph.D. (6.30M votes for) — for three-year terms, ratified BDO USA, P.C. as auditor, and approved executive compensation on an advisory basis. Routine governance for a small-cap diagnostics company; the lower vote count for Scott Kahn (~78% vs ~97% for Nova) may reflect shareholder dissatisfaction.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change
AI summary

XGN disclosed a personnel change (8-K Item 5.02, dated 2026-04-23). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

3/ANew insider — initial holdingsApr 213/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for XGN on 2026-04-21, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

+ 10 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysisdefenseworld.net·1d agoExagen Inc. (NASDAQ:XGN) Receives Consensus Recommendation of “Moderate Buy” from Analystsdefenseworld.net·9d agoInfuSystem (NYSE:INFU) & Exagen (NASDAQ:XGN) Head to Head Contrastdefenseworld.net·14d agoExagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Reviewdefenseworld.net·14d agoExagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokeragesdefenseworld.net·34d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$GRAL$NTRA$ILMN$TMO$DHR$GH
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport